Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Elite Sport and Development of Asthma

This study has been completed.
Imperial College London
Anti Doping Danmark
The Research Foundation of Bispebjerg Hospital
Ragnhild Ibsens Legat For Medicinsk Forskning
Information provided by (Responsible Party):
Thomas Lund, Bispebjerg Hospital Identifier:
First received: December 6, 2005
Last updated: May 15, 2012
Last verified: May 2012

International studies have shown that elite athletes have a high prevalence of respiratory symptoms and asthma as compared to normal subjects. It is unclear whether the increased prevalence of asthma in elite athletes reflects "traditional asthma" or whether it is a special form of "sports asthma". The treatment of elite athletes with asthma seems to vary widely, and only a few studies have focused on the treatment of elite athletes with asthma. Further knowledge of the pathogenesis of sports asthma would lead to a greater understanding and better treatment of the condition. This study will investigate the type of airway inflammation in elite athletes and examine the effect of treatment with inhaled steroids in combination with long-acting beta-agonists versus placebo in the same group.

Condition Intervention Phase
Drug: Seretide
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Elite Sport and Development of Asthma

Resource links provided by NLM:

Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • Eucapnic voluntary hyperventilation (EVH) [ Time Frame: End of study ] [ Designated as safety issue: No ]
  • Exhaled Nitric Oxide [ Time Frame: End of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Respiratory symptoms [ Time Frame: End of study ] [ Designated as safety issue: No ]
  • Lung function [ Time Frame: End of study ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: September 2005
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo inhaler (sugar powder)
Drug: Placebo
Inhaled sugar powder in a placebo inhaler
Active Comparator: Seretide
Seretide inhaler
Drug: Seretide
Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)


Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Elite athletes
  • Informed consent
  • Doctor diagnosed asthma

Exclusion Criteria:

  • Current smoker or more than 10 pack-years
  • Pregnancy, breast feeding or planning pregnancy during the study.
  • ICS within the last 4 weeks prior to visit 1.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262587

Respiratory and Allergy Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital
Copenhagen, Denmark, DK-2400 NV
Sponsors and Collaborators
Bispebjerg Hospital
Imperial College London
Anti Doping Danmark
The Research Foundation of Bispebjerg Hospital
Ragnhild Ibsens Legat For Medicinsk Forskning
Principal Investigator: Thomas Lund, MD Respiratory and Allergy Research Unit, Department of Respiratory Medicine
  More Information

No publications provided

Responsible Party: Thomas Lund, MD, Bispebjerg Hospital Identifier: NCT00262587     History of Changes
Other Study ID Numbers: 2005-061, (KF) 01 262958
Study First Received: December 6, 2005
Last Updated: May 15, 2012
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Bispebjerg Hospital:
Airway inflammation

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on March 01, 2015